Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT(1D) agonist sumatriptan

European Neuropsychopharmacology

Volumn 8, Issue 4, 1998, Pages 325-328

  Stern, Liat ^a   Zohar, Joseph ^a   Cohen, Rivka ^a   Sasson, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Drug resistant; Obsessive compulsive disorder; Sumatriptan treatment

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG RESISTANCE; FEMALE; HUMAN; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; DRUG RESISTANCE; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN AGONISTS; SINGLE-BLIND METHOD; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 0032402583     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00092-8     Document Type: Article

References (23)

1. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. rev. 1987. American Psychiatric Association, Washington DC, pp. 245-247.
2. Bastani B., Nash F., Meltzer H. Prolactin and cortisol response to MK-212 a serotonin agonist, in obsessive-compulsive disorder. Arch. Gen. Psychiatry. 47:1990;946-951.
3. Benjamin J., Greenberg B.D., Murphy D.L. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioural hormonal, cardiovascular and temperature effects. Psychopharmacology. 127:1996;140-149.
4. Hollander E., Fay M., Cohen B., Campeas R., Gorman J.M., Leibovitz M.R. Serotonergic and adrenergic sesnsitivity in obsessive-compulsive disorder: Behavioural findings. Am. J. Psychiatry. 145:1988;1015-1017.
5. Hollander E., Decaria C.M., Nitescue A.et al. Serotonergic function in obsessive-compulsive disorder: Behavioural and neuroendocrine to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch. Gen. Psychiatry. 49:1992;21-28.
6. Kaube H., Hoskin K.L., Goadsby P.J. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol. 109(3):1993;788-792.
7. 1A receptivity in obsessive-compulsive disorder: comparison of patients and controls. Arch. Gen. Psychiatry. 48:1991;540-547.
8. Peurotka S.J., McCarthy B.G. Sumatriptan (GR43175) interacts selectively with 5-HTIB and 5-HTlD binding sites. Eur. J. Pharmacol. 163:1989;133-136.
9. Peroutka, S.J., 1996. Drugs effective in the treatment of migraine. In: Hardman, J.G., Limbrid, L.E., Mollinof, P.B., Ruddon, R.W., Gilman, A.G. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th rev. ed. McGraw-Hill, New York, pp. 487-502.
10. Pigott T.A., Pato M.T., Bernstein S.E., Grover G.N., Hill J.L.et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive compulsive disorder: Behavioural and biological results. Arch. Gen. Psychiatry. 47:1990;926-932.
11. Pigott T.A., Zohar J., Hill J.L.et al. Metergoline blocks behavioural and neuroendocrine effects of orally administrated in patients with obsessive-compulsive disorder. Biol. Psychiatry. 29:1991;418-426.
12. Pigott, T.A., L'Heureux, F., Bernstein, S.E., Hill, J.L., Murphy, D.L., 1992. A controlled comparative therapeutic trial of clomipramine and m-chlorophenylpiperazin (mCPP) in patients with obsessive-compulsive disorder, NCDEU annual meeting abstracts, May 26-29.
13. lD receptors regulate 5-HT release in the rat raphe nuclei. Neuropsychopharmacology. 13(3):1995;249-260.
14. 1D receptors in the rat brain. Synapse. 22(1):1996;54-62.
15. 1A autoreceptors modulate 5-HT release in guinea pig dorsal raphe nucleus. Neuropharmachology. 33:1994;393-402.
16. Zohar J., Insel T. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment and pathophysiology. Biol. Psychiatry. 22:1987;667-687.
17. Zohar J., Mueller E.A., Insel T.R. Serotonin responsivity in obsessive compulsive disorder. Arch. Gen. Psychiatry. 44:1987;946-951.
18. Zohar J., Zohar-Kadouch R.C., Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs. 43:1992;210-218.
19. Zohar J., Kindler S. Serotonergic probes in obsessive-compulsive disorder. Int. Clin. Psychopharmacology. 7:1992;39-40.
20. 1D involved in obsessive-compulsive disorder? Eur. Neuropsychol. 6:1996;54-55.
21. Rubin R.T., Villanueva-Meyer J., Ananth J., Traimar P.G., Mena I. Regional 133Xe cerebral blood flow and cerebral 99mHMPAO uptake in unmedicated obsessive-compulsive disorder patients and matched normal control subjects: determination by high resolution single photon emission computed tomography. Arch. Gen. Psychiatry. 49:1992;695-702.
22. Swedo S.E., Rapoprt J.L., Cheslow D.L.et al. High prevalence of obsessive-compulsive symptoms in patients with sydenhams chorea. Am. J. Psychiatry. 146:1989;246-249.
23. Ducharme, V.G., Bouchard, C., Blier, P., 1996. Terminal 5-HT autoreceptor desensetization in the orbitofrontal cortex is produced exclusively by drugs effective in obsessive-compulsive disorder (OCD). Abstract, Society for neuroscience, 22, 525.5.